Alexis, A. F. ., Merola, J. F. ., Zhong, Y. ., Zhuo, J. ., Becker, B. ., Napoli, A. ., Ross, J. ., Beaumont, J. ., DeRosa, M. ., Banerjee, S. ., & Armstrong, A. W. . (2024). Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch as Assessed by the Psoriasis Symptoms and Signs Diary. SKIN The Journal of Cutaneous Medicine, 8(2), s358. https://doi.org/10.25251/skin.8.supp.358